专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

WO0023806A9 DETECTION AND QUANTIFICATION OF VANCOMYCIN IN BIOLOGICAL FLUIDS 审中-公开
标题翻译： VANCOMYCIN在生物流体中的检测和定量
公开(公告)号：WO0023806A9
公开(公告)日：2000-10-26
申请号：PCT/US9924270
申请日：1999-10-15
申请人： ABBOTT LAB
发明人： ADAMCZYK MACIEJ , BRATE ELAINE M , PERKOWITZ MARY M , REGE SUSHIL D
IPC分类号： G01N33/53 , C07K16/44 , C12N5/10 , C12N15/02 , C12R1/91 , G01N33/533 , G01N33/542 , G01N33/577 , G01N33/94 , G01N33/58 , C07K16/14 , G01N33/531
CPC分类号： C07K16/44 , G01N33/533 , G01N33/9446
摘要： Immunoassay reagents, methods and test kits for the specific quantification of vancomycin in a test sample are disclosed. The reagent comprises antibodies prepared with immunogens of Figure 6 wherein P is an immunogenic carrier material and X is a linking moiety. Also described is the synthesis of labeled reagents of Figure 8 wherein Q is a detectable moiety, preferably fluorescein or a fluorescein derivative, and X is a linking moiety.
摘要翻译：公开了用于测试样品中万古霉素的特异性定量的免疫测定试剂，方法和测试试剂盒。试剂包含用图6的免疫原制备的抗体，其中P是免疫原性载体材料，X是连接部分。还描述了图8的标记试剂的合成，其中Q是可检测部分，优选荧光素或荧光素衍生物，X是连接部分。

42. 发明申请

WO00048620A1 YEAST CELL WALL PEPTIDES AND ANTIBODIES THERETO 审中-公开
标题翻译： YEAST细胞壁蛋白和抗体
公开(公告)号：WO00048620A1
公开(公告)日：2000-08-24
申请号：PCT/US2000/004228
申请日：2000-02-18
IPC分类号： G01N33/50 , A61K38/00 , A61K39/395 , A61P31/00 , C07K7/06 , C07K14/39 , C07K16/14 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/569 , G01N33/577
CPC分类号： C07K16/14 , A61K38/00 , A61K2039/505 , C07K14/39 , C07K2317/34
摘要： The present invention provides a number of yeast cell wall proteins that are hydrophobic and are involved in hydrophobically mediated pathogenic events. The present invention also provides antibodies to these proteins, as well as methods of inhibiting hydrophobically mediated pathogenesis events comprising administering these antibodies.
摘要翻译：本发明提供了许多疏水性并涉及疏水介导的致病事件的酵母细胞壁蛋白。本发明还提供了对这些蛋白质的抗体，以及抑制疏水介导的发病事件的方法，包括施用这些抗体。

43. 发明申请

WO00024773A3 INHIBITION OF TRANSGLUTAMINASE-MEDIATED MICROBIAL INFECTION OF A MAMMALIAN HOST 审中-公开
标题翻译：转移蛋白酶介导的感染MAMMALIAN HOST的微生物感染的抑制
公开(公告)号：WO00024773A3
公开(公告)日：2000-08-10
申请号：PCT/US1999/025043
申请日：1999-10-26
IPC分类号： G01N33/569 , A61K38/00 , A61K39/00 , A61K39/02 , A61K39/12 , A61K39/395 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/18 , A61P43/00 , C07K14/00 , C07K14/40 , C07K16/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12P21/08 , G01N33/577 , C07K16/14 , C12N15/11
CPC分类号： C07K14/40 , A61K39/00
摘要： The infection of a mammalian host by a microorganism Candida albicans can be prevented or treated through the administration the substrate for transglutaminases Hwp or antibodies against this substrates that inhibit the transglutaminase-mediated interaction of the microorganism with the mammalian host. These compounds may be used in the identification, prevention or treatment of microbial infection of mammalian hosts such as immunocompromised or immunosuppressed humans, for example, those having AIDS or undergoing transplantation or anti-cancer therapy.
摘要翻译：哺乳动物宿主由微生物感染白念珠菌可以通过给予转谷氨酰胺酶Hwp的底物或针对该底物的抗体来抑制转谷氨酰胺酶介导的微生物与哺乳动物宿主的相互作用的预防或治疗。这些化合物可用于鉴定，预防或治疗哺乳动物宿主例如免疫受损或免疫抑制的人，例如具有AIDS或进行移植或抗癌治疗的哺乳动物宿主的微生物感染。

44. 发明申请

WO0017344A8 RESPONSE REGULATOR CaSSK1 审中-公开
标题翻译：反应调节剂CaSSK1
公开(公告)号：WO0017344A8
公开(公告)日：2000-05-11
申请号：PCT/US9922218
申请日：1999-09-23
申请人： UNIV GEORGETOWN MED CENTER , CALDERONE RICHARD A , CALERA JOSE
发明人： CALDERONE RICHARD A , CALERA JOSE
IPC分类号： A61K39/00 , C07K14/40 , C12N9/12 , C12N15/11 , A61K35/72 , C07K16/14 , C07K16/40 , C12N1/19 , C12N15/54 , C12N15/81 , C12Q1/48 , C12Q1/68 , G01N33/573
CPC分类号： C12N9/1223 , A61K39/00 , C07K14/40
摘要： The present invention relates to nucleic acids encoding a response regulator, CaSsk1p, and methods for use, as well as describes the construction and characterization and use of a DELTA cassk1 mutant of C. albicans and methods of use.
摘要翻译：本发明涉及编码响应调节剂CaSsk1p的核酸及其使用方法，并且描述了白色念珠菌的DELTA cassk1突变体的构建和表征和用途及其使用方法。

45. 发明申请

WO00023806A1 DETECTION AND QUANTIFICATION OF VANCOMYCIN IN BIOLOGICAL FLUIDS 审中-公开
标题翻译：万古霉素在生物流体中的检测和定量
公开(公告)号：WO00023806A1
公开(公告)日：2000-04-27
申请号：PCT/US1999/024270
申请日：1999-10-15
IPC分类号： G01N33/53 , C07K16/44 , C12N5/10 , C12N15/02 , C12R1/91 , G01N33/533 , G01N33/542 , G01N33/577 , G01N33/94 , G01N33/58 , C07K16/14 , G01N33/531
CPC分类号： C07K16/44 , G01N33/533 , G01N33/9446
摘要： Immunoassay reagents, methods and test kits for the specific quantification of vancomycin in a test sample are disclosed. The reagent comprises antibodies prepared with immunogens of Figure 6 wherein P is an immunogenic carrier material and X is a linking moiety. Also described is the synthesis of labeled reagents of Figure 8 wherein Q is a detectable moiety, preferably fluorescein or a fluorescein derivative, and X is a linking moiety.
摘要翻译：本发明涉及用于特异性定量测试样品中万古霉素的免疫试剂，方法和测试试剂盒。该试剂包含用根据图6的通式的免疫原制备的抗体，其中P是免疫原性载体材料并且X是接头部分。本发明还涉及标记的试剂。根据图8的公式，Q是可检测部分，优选荧光素或荧光素衍生物，并且X是接头部分。

46. 发明申请

WO00017344A1 RESPONSE REGULATOR CaSSK1 审中-公开
标题翻译：反应调节剂CaSSK1
公开(公告)号：WO00017344A1
公开(公告)日：2000-03-30
申请号：PCT/US1999/022218
申请日：1999-09-23
IPC分类号： A61K39/00 , C07K14/40 , C12N9/12 , C12N15/11 , A61K35/72 , C07K16/14 , C07K16/40 , C12N1/19 , C12N15/54 , C12N15/81 , C12Q1/48 , C12Q1/68 , G01N33/573
CPC分类号： C12N9/1223 , A61K39/00 , C07K14/40
摘要： The present invention relates to nucleic acids encoding a response regulator, CaSsk1p, and methods for use, as well as describes the construction and characterization and use of a DELTA cassk1 mutant of C. albicans and methods of use.
摘要翻译：本发明提供编码反馈调节剂CaSsk1p的核酸及其使用方法。本发明还涉及白色念珠菌Δcassk1突变体的构建，表征和使用及其使用方法。

47. 发明申请

WO99055874A3 NUCLEIC ACIDS OF THE M ANTIGEN GENE OF HISTOPLASMA CAPSULATUM, ANTIGENS, VACCINES AND ANTIBODIES, METHODS AND KITS FOR DETECTING HISTOPLASMOSIS 审中-公开
标题翻译：抗病原体抗原基因，抗原，疫苗和抗体的核酸，用于检测HISTOPLASMOSIS的方法和工具
公开(公告)号：WO99055874A3
公开(公告)日：2000-01-06
申请号：PCT/US1999/009151
申请日：1999-04-27
IPC分类号： A61K39/00 , C07K14/37 , C12N15/31 , C07K16/14
CPC分类号： C07K14/37 , A61K39/00
摘要： The present invention provides the nucleotide sequence of the M antigen gene of H. capsulatum, which is set forth in the Sequence Listing as SEQ ID NO:1, a nucleic acid having the nucleotide sequence complementary thereto, and nucleic acids having a nucleotide sequence which is substantially the same as the foregoing nucleotide sequences. The present invention also provides vectors and host expressions systems containing the foregoing nucleic acids, and isolated or recombinantly-produced antigens encoded by the foregoing nucleic acids. The present invention further provides antibodies generated against the foregoing antigens, and methods and kits for detecting a previous or current Histoplasma capsulatum infection in a subject, and for diagnosing histoplasmosis.
摘要翻译：本发明提供了序列表中列出的H. capsulatum的M抗原基因的核苷酸序列，其核苷酸序列互补的核酸和具有与SEQ ID NO：1相同的核苷酸序列的核酸与上述核苷酸序列基本相同。本发明还提供了含有上述核酸的载体和宿主表达系统，以及由上述核酸编码的分离或重组产生的抗原。本发明还提供针对上述抗原产生的抗体，以及用于检测受试者中先前或当前的组织胞浆荚膜感染以及用于诊断组织胞浆菌病的方法和试剂盒。

48. 发明申请

WO98045333A1 METHOD FOR PRODUCTION OF ANTIBODIES TO SPECIFIC SITES OF RAPAMYCIN 审中-公开
标题翻译：用于生产抗RAPAMYCIN特异性位点的抗体的方法
公开(公告)号：WO98045333A1
公开(公告)日：1998-10-15
申请号：PCT/CA1998/000361
申请日：1998-04-09
IPC分类号： G01N33/53 , C07K14/435 , C07K14/765 , C07K16/12 , C07K16/14 , C12N5/10 , C12N15/02 , C12P21/08 , G01N33/577
CPC分类号： C07K16/14
摘要： This invention relates to the production of polyclonal and monoclonal antibodies to specific sites of rapamycin (Sirolimus). The reactivity of these poly and monoclonal antibodies make them particularly useful for immunoassays for therapeutic drug monitoring (TDM). These immunoassays or TDM kits may include polyclonal or monoclonal antibodies to specific sites of rapamycin. These kits may also include various combinations of polyclonal antibodies, polyclonal and monoclonal antibodies or a panel of monoclonal antibodies. Rapamycin conjugate immunogens are prepared for the immunization of a host animal to produce antibodies directed against specific regions of the rapamycin molecule. By determining the specific binding region of particular antibody, immunoassays which are capable of distinguishing between the parent molecule, active metabolites, inactive metabolites and other structurally similar immunosuppressant compounds are developed. The use of divinyl sulfone (DVS) as the linker arm molecule for forming rapamycin-protein conjugate immunogens is described. DVS-linked rapamycin-protein conjugates were found to elicit antibodies with greater specificity to the rapamycin molecule than succinate linked conjugates.
摘要翻译：本发明涉及针对雷帕霉素（西罗莫司）特定部位的多克隆和单克隆抗体的产生。这些多抗和单克隆抗体的反应性使其对治疗药物监测（TDM）的免疫测定特别有用。这些免疫测定或TDM试剂盒可以包括针对雷帕霉素的特定位点的多克隆或单克隆抗体。这些试剂盒还可以包括多克隆抗体，多克隆和单克隆抗体或一组单克隆抗体的各种组合。制备雷帕霉素结合物免疫原用于免疫宿主动物以产生针对雷帕霉素分子的特定区域的抗体。通过确定特定抗体的特异性结合区域，开发了能够区分亲本分子，活性代谢物，无活性代谢物和其他结构类似的免疫抑制剂化合物的免疫测定。描述了使用二乙烯基砜（DVS）作为形成雷帕霉素 - 蛋白质结合物免疫原的连接臂分子。发现DVS连接的雷帕霉素 - 蛋白质缀合物比琥珀酸酯连接的缀合物引起对雷帕霉素分子具有更高特异性的抗体。

49. 发明申请

WO98039424A1 DNA ENCODING PNEUMOCYSTIS CARINII PROTEASE 审中-公开
标题翻译： DNA编码肺炎球菌CARINII蛋白
公开(公告)号：WO98039424A1
公开(公告)日：1998-09-11
申请号：PCT/GB1998/000704
申请日：1998-03-05
IPC分类号： G01N33/50 , C07K16/14 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/58 , C12N15/02 , C12N15/09 , C12N15/55 , C12P21/08 , G01N33/15
CPC分类号： C12N9/58
摘要： The invention relates to a novel Pneumocystis carinii protease with counterparts in P.carinii infecting various different species, including human, as well as nucleic acids encoding it.
摘要翻译：本发明涉及一种新颖的卡氏肺囊虫病毒（Pneumocystis carinii）蛋白酶，其与感染包括人在内的各种不同物种的卡氏菌属的对应物以及编码它的核酸。

50. 发明申请

WO9535111A3 USE OF BETA GALNAC(1-4) BETA GAL CONJUGATES TO TREAT CANDIDA INFECTION 审中-公开
标题翻译：使用加泰罗尼加（1〜4）试验结合剂治疗糖尿病感染
公开(公告)号：WO9535111A3
公开(公告)日：1996-03-14
申请号：PCT/IB9500514
申请日：1995-06-16
申请人： SYNTHETIC PEPTIDES INC
发明人： YU LEI , LEE KOK KHEONG , SHETH HASMUKH B , IRVIN RANDALL T , HODGES ROBERT S
IPC分类号： C12N15/02 , A61K31/70 , A61K31/7024 , A61K31/7028 , A61K38/00 , A61K39/395 , A61K47/48 , A61P31/04 , C07H13/06 , C07H15/04 , C07K16/12 , C07K16/14 , C12P21/08 , C12R1/91
CPC分类号： A61K31/70 , A61K38/00 , A61K47/6923 , C07K16/14
摘要： A method of treating Candida albicans infection is disclosed. In one embodiment, for treatment of oral or vaginal infection, the treatment is by topical application of a composition of conjugates that are each composed of a carrier structure and multiple βGalNac(1-4)βGal moieties attached to the structure. In another embodiment, for treatment of systemic infection, the treatment is by parenteral administration of a humanized form of a mouse monoclonal antibody produced by mouse hybridoma cell line Fm16 or cell line PK99H.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式